Kidney Fibrosis-Pipeline Review, H1 2017

Kidney Fibrosis-Pipeline Review, H1 2017


  • Products Id :- GMDHC9242IDB
  • |
  • Pages: 131
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Kidney Fibrosis-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Kidney Fibrosis-Pipeline Review, H1 2017, provides an overview of the Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline landscape.

Accumulation of extracellular matrix in the kidney causes kidney fibrosis. It is a progressive disorder characterized by glomerulosclerosis and tubulointerstitial fibrosis and may lead to detrimental effects on the kidney functioning. Predisposing factors are trauma, injury, infections, surgery, environmental factors and exposure to chemicals or radiation. Symptoms include pain, problems related to urination, nausea and vomiting. The condition may be managed with medication and kidney transplant.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Kidney Fibrosis-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Kidney Fibrosis (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Kidney Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 4, 25 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively.

Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Kidney Fibrosis (Genito Urinary System And Sex Hormones).

The pipeline guide reviews pipeline therapeutics for Kidney Fibrosis (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Kidney Fibrosis (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Kidney Fibrosis (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Kidney Fibrosis (Genito Urinary System And Sex Hormones)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Kidney Fibrosis (Genito Urinary System And Sex Hormones).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Kidney Fibrosis-Overview

Kidney Fibrosis-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Kidney Fibrosis-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Kidney Fibrosis-Companies Involved in Therapeutics Development

AbbVie Inc

Allergan Plc

Angion Biomedica Corp

Apollo Endosurgery Inc

BiOrion Technologies BV

Cellmid Ltd

Epigen Biosciences Inc

Evotec AG

Galectin Therapeutics Inc

GenKyoTex SA

Horizon Pharma Plc

Intercept Pharmaceuticals Inc

Isarna Therapeutics GmbH

MorphoSys AG

Pharmaxis Ltd

ProMetic Life Sciences Inc

Regulus Therapeutics Inc

Sirnaomics Inc

Symic Biomedical Inc

Vascular Biogenics Ltd

Kidney Fibrosis-Drug Profiles

ANG-3070-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ANG-3586-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ANG-4021-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BOT-191-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CAB-102-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cenicriviroc mesylate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CT-140-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cysteamine DR-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Inhibit Galectin-3 for Liver Fibrosis, Pulmonary Fibrosis and Kidney Fibrosis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs for Tissue Fibrosis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate Smad7 for Hypertensive Cardiomyopathy and Kidney Fibrosis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GKT-136901-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GRMD-02-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ICG-001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INT-767-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IP-9-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ISTH-0047-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LJ-1888-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Lpathomab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

melittin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MOR-107-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P-007-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PBI-4050-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PXS-4820-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PXS-5033A-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Agonize ALK and BMP Receptors for Alport Syndrome, Kidney Diseases, Metabolic Disorders and Osteoarthritis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RG-012-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SB-300-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize AlphaV and Beta6 for Fibrosis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize LPA1 Receptor for Metastatic Breast Cancer and Renal Fibrosis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Cyclophilin D for Obesity and Renal Fibrosis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit LOXL2 for Idiopathic Pulmonary Fibrosis, Kidney Fibrosis, Liver Fibrosis and Non-Alcoholic Steatohepatitis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SOL-1-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

STP-705-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Agonize BMP7 Receptor for Renal Fibrosis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TEW-7197-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VB-201-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VB-703-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Wnt-001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Kidney Fibrosis-Dormant Projects

Kidney Fibrosis-Product Development Milestones

Featured News & Press Releases

Apr 25, 2017: Galectin Therapeutics Receives Notice of Japanese Decision to Grant a Composition of Matter Patent for GR-MD-02

Feb 21, 2017: MorphoSys's Subsidiary Lanthio Pharma Initiates First-in-Human Clinical Study with Lanthipeptide MOR107

Nov 18, 2016: ProMetic presents PBI-4050's positive effect on diabetic patients' kidneys at the American Society of Nephrology Annual Meeting

Jul 12, 2016: Galectin Therapeutics Receives Notice of Australian Patent to be Granted for the Use of GR-MD-02 in Liver, Kidney, Lung or Heart Fibrosis

Nov 12, 2015: Regulus Announces Grant of Patent Covering Lead microRNA Therapeutics

Nov 09, 2015: ProMetic's PBI-4050 data on renal fibrosis and pancreatic function featured at the American Society of Nephrology's annual meeting

Oct 29, 2015: ProMetic's PBI-4050 Cleared to Commence Clinical Trial in Patients With Type 2 Diabetes and Multi-Organ Fibrosis in Europe

Oct 05, 2015: Regulus to Present Additional Preclinical Data Supporting RG-012 as a Novel microRNA Therapeutic in Development for Alport Syndrome at ASN's Kidney Week 2015

Aug 13, 2015: Galectin Therapeutics Receives U.S. Patent Notice of Allowance for Use of Pectin Compounds to Reduce Fibrosis in Multiple Diseases

Oct 14, 2014: Regulus Therapeutics To Present New Preclinical Data on Multiple Programs At 10th Annual Oligonucleotide Therapeutics Society Meeting

Aug 05, 2014: Galectin Therapeutics Receives U.S. Patent for GR-MD-02 Composition of Matter

Jul 25, 2014: Galectin Therapeutics to Host Webcast to Discuss Findings From Cohort 2 of Phase 1 Clinical Trial of GR-MD-02 in Fatty Liver Disease With Advanced Fibrosis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development for Kidney Fibrosis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Kidney Fibrosis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Kidney Fibrosis-Pipeline by AbbVie Inc, H1 2017

Kidney Fibrosis-Pipeline by Allergan Plc, H1 2017

Kidney Fibrosis-Pipeline by Angion Biomedica Corp, H1 2017

Kidney Fibrosis-Pipeline by Apollo Endosurgery Inc, H1 2017

Kidney Fibrosis-Pipeline by BiOrion Technologies BV, H1 2017

Kidney Fibrosis-Pipeline by Cellmid Ltd, H1 2017

Kidney Fibrosis-Pipeline by Epigen Biosciences Inc, H1 2017

Kidney Fibrosis-Pipeline by Evotec AG, H1 2017

Kidney Fibrosis-Pipeline by Galectin Therapeutics Inc, H1 2017

Kidney Fibrosis-Pipeline by GenKyoTex SA, H1 2017

Kidney Fibrosis-Pipeline by Horizon Pharma Plc, H1 2017

Kidney Fibrosis-Pipeline by Intercept Pharmaceuticals Inc, H1 2017

Kidney Fibrosis-Pipeline by Isarna Therapeutics GmbH, H1 2017

Kidney Fibrosis-Pipeline by MorphoSys AG, H1 2017

Kidney Fibrosis-Pipeline by Pharmaxis Ltd, H1 2017

Kidney Fibrosis-Pipeline by ProMetic Life Sciences Inc, H1 2017

Kidney Fibrosis-Pipeline by Regulus Therapeutics Inc, H1 2017

Kidney Fibrosis-Pipeline by Sirnaomics Inc, H1 2017

Kidney Fibrosis-Pipeline by Symic Biomedical Inc, H1 2017

Kidney Fibrosis-Pipeline by Vascular Biogenics Ltd, H1 2017

Kidney Fibrosis-Dormant Projects, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AbbVie Inc, Allergan Plc, Angion Biomedica Corp, Apollo Endosurgery Inc, BiOrion Technologies BV, Cellmid Ltd, Epigen Biosciences Inc, Evotec AG, Galectin Therapeutics Inc, GenKyoTex SA, Horizon Pharma Plc, Intercept Pharmaceuticals Inc, Isarna Therapeutics GmbH, MorphoSys AG, Pharmaxis Ltd, ProMetic Life Sciences Inc, Regulus Therapeutics Inc, Sirnaomics Inc, Symic Biomedical Inc, Vascular Biogenics Ltd

select a license

Single User License
USD 2000 INR 130100
Site License
USD 4000 INR 260200
Corporate User License
USD 6000 INR 390300

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com